Drug News

Outrun Therapeutics Secures $10M Seed Financing to Advance Protein Stabilization Pipeline

Outrun Therapeutics, a pioneering company in the field of protein stabilization through E3 ligase inhibition, has emerged from stealth mode with a significant milestone: a $10 million seed financing round led by M Ventures and MP Healthcare Venture Management. This funding injection will drive Outrun’s mission to develop a robust pipeline of small molecule E3 ligase inhibitors, targeting various diseases including cancer and neurology.

At the core of Outrun’s approach lies its proprietary E3 ligase platform, which facilitates protein stabilisation “at source,” thereby restoring the body’s natural disease suppression mechanisms. By inhibiting specific E3 ligases, Outrun aims to prevent protein degradation, effectively maintaining the balance of critical proteins involved in disease processes. This innovative strategy holds promise for a wide range of therapeutic applications, particularly in addressing hard-to-treat solid tumors.

The significance of E3 ligase inhibition in protein stabilisation cannot be overstated. Cells possess intricate mechanisms to combat disease, and empowering these mechanisms represents a potent therapeutic approach. Outrun’s platform enables the identification of novel E3 ligase targets across multiple disease areas, offering a new frontier in precision medicine. By selectively stabilising proteins, Outrun aims to expand the spectrum of treatable diseases while minimizing side effects.

Outrun’s platform incorporates cutting-edge technology, including high-throughput screening methods and engineered protein sensors (EPS), to accelerate the discovery of E3 ligase inhibitors. This technology allows for precise assessment of target specificity and selectivity, streamlining the drug discovery process and enhancing the binding affinity of potential therapeutics. The scalability and modularity of Outrun’s approach position it as a leader in developing next-generation small molecule drugs targeting E3 ligases.

Dr. Carolyn Porter, CEO of Outrun Therapeutics, underscores the importance of protein stabilisation as a complementary approach to protein degradation in disease management. Leveraging their expertise in E3 ligase biology and protein-to-protein interactions, combined with their proprietary discovery platform, Outrun is poised to unlock the therapeutic potential of this innovative modality.

The endorsement from investors like MP Healthcare Venture Management and M Ventures reflects confidence in Outrun’s pioneering approach and transformative potential. Dr. Jeffrey Moore of MP Healthcare Venture Management expresses optimism about the transformative impact of protein stabilisation via E3 ligase inhibition across various disease areas. Dr. Bauke Anninga of M Ventures emphasizes the competitive edge provided by Outrun’s novel platform in reducing discovery timelines and building a first-in-class pipeline.

Outrun’s journey began at the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee, under the guidance of Prof. Satpal Virdee. Today, Outrun boasts a seasoned management team, a strong board, and a distinguished Scientific Advisory Board comprising experts in ubiquitylation and oncology. With the backing of leading venture capital investors, Outrun is poised to revolutionize the landscape of protein stabilisation and usher in a new era of precision medicine.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker